Citius Pharmaceuticals
CTXR
57 hedge funds and large institutions have $11.8M invested in Citius Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 24 reducing their positions, and 22 closing their positions.
430% more call options, than puts
Call options by funds: $106K | Put options by funds: $20K
0.16% less ownership
Funds ownership: 0.68% → 0.52% (-0.16%)
21% less funds holding
Funds holding: 72 → 57 (-15)
34% less capital invested
Capital invested by funds: $17.9M → $11.8M (-$6.07M)
68% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 22
75% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$444K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.4K |
| 4 |
VF
Virtu Financial
New York
|
+$67.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$62.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.94M |
| 2 |
Goldman Sachs
New York
|
-$773K |
| 3 |
Millennium Management
New York
|
-$599K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$495K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$320K |
CTXR Hedge Fund Activity: Q3 2024 in Review
57 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2024, worth a combined $11.8M — down 34% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CTXR and 7 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 6 added.
The largest buyer was Squarepoint, opening a new position worth an estimated $444K. The largest seller was Armistice Capital, cutting an estimated $1.94M.
- 57 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2024, down from 72 in Q2 2024.
- Funds reported $11.8M of Citius Pharmaceuticals stock for Q3 2024, down 34% quarter-over-quarter.
- 7 funds opened new Citius Pharmaceuticals positions in Q3 2024 and 22 closed out, a net change of -15 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2024 was Squarepoint, an estimated $444K added.
- The largest Citius Pharmaceuticals seller in Q3 2024 was Armistice Capital, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2024.